secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2023-10-12T23:59:59+00:00
Accession:  0000950170-23-053109
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics reports RLY-4008 data: 35% ORR in FGFR2 fusions; cash runway extended to 2H2026
--------------------------------------------------------------------------------

- RLY-4008 achieved 35% ORR in FGFR2-fusion tumors (n=26) and 40% ORR in HR+/HER2- breast cancer (n=10); durable responses of ≥6 months in most responders.
- In FGFR2-amplified tumors, 24% ORR (8/34) across multiple tumor types; early signals in FGFR2 mutations (3 PRs).
- Safety profile consistent with prior data: no Grade 4/5 adverse events; off-target toxicities clinically insignificant.
- Pipeline update: plans to initiate RLY-2608 + fulvestrant + CDK4/6 triplet by YE 2023; pause RLY-2139 (CDK2 inhibitor) development.
- Cash runway extended by ~1 year, now sufficient into 2H2026; CCA commercial readiness paused to focus on tumor-agnostic opportunity.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017023053109/0000950170-23-053109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017023053109/rlay-20231012.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-053109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer